-
1.发明申请公开(公告)号：US20180196057A1
公开(公告)日：2018-07-12
申请号：US15851502
申请日：2017-12-21
发明人： Fernando Jose Rebelo do Couto , Zhiming Liao , Andrea Muranyi , Kandavel Shanmugam , Shalini Singh , Yifei Zhu
IPC分类号： G01N33/574 , C07K16/22 , C07K16/30
CPC分类号： G01N33/57496 , C07K16/22 , C07K16/30 , C07K2317/20 , C07K2317/34 , C07K2317/92 , G01N2333/485
摘要： The invention provides anti-human pro-epiregulin and anti-human amphiregulin antibodies and methods of using the same. Anti-EREG antibodies raised against amino acids 148-169 and 156-169 of the human EREG protein, and anti-AREG antibodies raised against amino acids 238-252 of the human AREG protein are disclosed. Methods of using these antibodies to detect EREG and AREG and kits and other products for performing such methods are also disclosed.
-
2.发明申请G-Alpha Interacting Vesicle Associated Protein (GIV) as a Predictive Marker in Stage II Colorectal Cancer 审中-公开G-Alpha相互作用的囊泡相关蛋白（GIV）作为II期结肠直肠癌中的预测标记公开(公告)号：US20170038385A1
公开(公告)日：2017-02-09
申请号：US15238662
申请日：2016-08-16
申请人： Ventana Medical Systems, Inc. , The Regents of the University of California , The United States of America as Represented by the Department of Veterans Affairs , Hoffmann-La Roche, Inc.
发明人： Katherine Leith , Ulrich-Peter Rohr , Shalini Singh , Pradipta Ghosh , Song Hu , Bonnie LaFleur , Andrea Muranyi , Kandavel Shanmugam
IPC分类号： G01N33/574 , C12Q1/68
CPC分类号： G01N33/57419 , C12Q1/6886 , C12Q2600/112 , C12Q2600/158 , G01N2800/56
摘要： Provided herein are methods of analyzing stage II colorectal cancer (CRC) samples (such as those that are mis-match repair proficient, pMMR), by scoring G-alpha interacting vesicle associated protein (GIV, also known as girdin) full-length (GIV-fl) expression in combination with lymphovascular invasion (LVI) status or clinical variables. The disclosed methods can be used to identify GIV-fl expressing tumors that are likely to recur (high risk) and those that are not likely to recur (high risk). Subjects identified as having a high risk CRC can be selected to receive chemotherapy or biotherapy for the CRC. Thus, in some examples, the disclosed methods can be used to identify CRC tumors that are likely to respond to chemotherapy or biotherapy. Also provided are computer implemented methods, systems, and kits that can be used with these methods.
摘要翻译： 本文提供了通过对G-α相互作用的囊泡相关蛋白（GIV，也称为girdin）全长（GIV）进行评分来分析II期结肠直肠癌（CRC）样品（例如那些与精子错误匹配的pMMR） GIV-fl）表达与淋巴血管侵袭（LVI）状态或临床变量组合。 所公开的方法可用于鉴定可能复发（高风险）的GIV-fl表达的肿瘤和不可能再发生的（高风险）的GIV-fl表达的肿瘤。 被确定为具有高风险CRC的受试者可以选择接受化学疗法或生物疗法用于CRC。 因此，在一些实例中，所公开的方法可用于鉴定可能对化学疗法或生物疗法作出反应的CRC肿瘤。 还提供了可以与这些方法一起使用的计算机实现的方法，系统和工具包。
-
3.发明公开公开(公告)号：US20240027463A1
公开(公告)日：2024-01-25
申请号：US18351374
申请日：2023-07-12
发明人： Fernando Jose Rebelo do Couto , Zhiming Liao , Andrea Muranyi , Kandavel Shanmugam , Shalini Singh , Yifei Zhu
IPC分类号： G01N33/574 , C07K16/22 , C07K16/30
CPC分类号： G01N33/57496 , C07K16/22 , C07K16/30 , C07K2317/34 , C07K2317/20 , C07K2317/92 , G01N2333/485
摘要： The invention provides anti-human pro-epiregulin and anti-human amphiregulin antibodies and methods of using the same. Anti-EREG antibodies raised against amino acids 148-169 and 156-169 of the human EREG protein, and anti-AREG antibodies raised against amino acids 238-252 of the human AREG protein are disclosed. Methods of using these antibodies to detect EREG and AREG and kits and other products for performing such methods are also disclosed.
-
4.发明授权公开(公告)号：US10852304B2
公开(公告)日：2020-12-01
申请号：US15851502
申请日：2017-12-21
发明人： Fernando Jose Rebelo do Couto , Zhiming Liao , Andrea Muranyi , Kandavel Shanmugam , Shalini Singh , Yifei Zhu
IPC分类号： C07K16/00 , G01N33/574 , C07K16/22 , C07K16/30
摘要： The invention provides anti-human pro-epiregulin and anti-human amphiregulin antibodies and methods of using the same. Anti-EREG antibodies raised against amino acids 148-169 and 156-169 of the human EREG protein, and anti-AREG antibodies raised against amino acids 238-252 of the human AREG protein are disclosed. Methods of using these antibodies to detect EREG and AREG and kits and other products for performing such methods are also disclosed.
-
5.发明授权公开(公告)号：US11747339B2
公开(公告)日：2023-09-05
申请号：US16949252
申请日：2020-10-21
发明人： Fernando Jose Rebelo do Couto , Zhiming Liao , Andrea Muranyi , Kandavel Shanmugam , Shalini Singh , Yifei Zhu
IPC分类号： C07K16/00 , G01N33/574 , C07K16/22 , C07K16/30
CPC分类号： G01N33/57496 , C07K16/22 , C07K16/30 , C07K2317/20 , C07K2317/34 , C07K2317/92 , G01N2333/485
摘要： The invention provides anti-human pro-epiregulin and anti-human amphiregulin antibodies and methods of using the same. Anti-EREG antibodies raised against amino acids 148-169 and 156-169 of the human EREG protein, and anti-AREG antibodies raised against amino acids 238-252 of the human AREG protein are disclosed. Methods of using these antibodies to detect EREG and AREG and kits and other products for performing such methods are also disclosed.
-
6.发明公开公开(公告)号：US20230204585A1
公开(公告)日：2023-06-29
申请号：US18050425
申请日：2022-10-27
发明人： Michael Barnes , Joerg Bredno , Brian D. Kelly , Jim F. Martin , Andrea Muranyi , Carlos T. Pineda , Kandavel Shanmugam
IPC分类号： G01N33/574 , G01N33/74 , G06T7/00 , G06V10/25 , G06V10/771
CPC分类号： G01N33/57419 , G01N33/5748 , G01N33/74 , G06T7/0012 , G06V10/25 , G06V10/771 , G01N2333/71 , G06T2207/10056 , G06T2207/30096
摘要： Methods and systems for predictive measures of anti-EGFR therapy response in wild type RAS/EGFR+ samples, e.g., histochemical staining methods for staining EGFR, AREG, and EREG, digital analysis of stained slides, and scoring algorithms that allow prediction of a response to anti-EGFR therapies. Analysis of the stained slides and scoring algorithms may include but are not limited to: a percent tumor cell positivity, computerized clustering algorithms, area density (e.g., area of tumor positive for one or more markers over total tumor area), average intensity (e.g., computerized methodology measuring average gray scale pixel intensity), average intensity broken down according to membrane, cytoplasmic, or punctate staining patterns), or any other appropriate parameter or combination of parameters. The methods of the present invention allow for resolving spatial expression patterns of the ligands and the receptor to determine what patterns are predictive for response to anti-EGFR therapies.
-
7.发明申请公开(公告)号：US20210063403A1
公开(公告)日：2021-03-04
申请号：US16949252
申请日：2020-10-21
发明人： Fernando Jose Rebelo do Couto , Zhiming Liao , Andrea Muranyi , Kandavel Shanmugam , Shalini Singh , Yifei Zhu
IPC分类号： G01N33/574 , C07K16/22 , C07K16/30
摘要： The invention provides anti-human pro-epiregulin and anti-human amphiregulin antibodies and methods of using the same. Anti-EREG antibodies raised against amino acids 148-169 and 156-169 of the human EREG protein, and anti-AREG antibodies raised against amino acids 238-252 of the human AREG protein are disclosed. Methods of using these antibodies to detect EREG and AREG and kits and other products for performing such methods are also disclosed.
-
公开(公告)号：US20190269716A1
公开(公告)日：2019-09-05
申请号：US16412057
申请日：2019-05-14
申请人： VENTANA MEDICAL SYSTEMS, INC. , ROCHE SEQUENCING SOLUTIONS INC. , Charité - Universitätsmedizin Berlin Gliedkörperschaft der Freien Universität Berlin Und der Humbold
发明人： Pia Herrmann , Katharina Ilm , Katherine F. Leith , Andrea Muranyi , Ulrich-Peter Rohr , Kandavel Shanmugam , Shalini Singh , Ulrike Stein
IPC分类号： A61K31/7072 , A61P35/04 , C12Q1/686 , G01N1/30 , A61K31/52 , A61K31/513 , C12Q1/6886 , G01N21/88
摘要： A combination of mismatch repair (MMR) and Metastasis Associated in Colon Cancer 1 (MACC1) gene expression status of the patient serve as a basis for risk stratification of early stage colon cancer patients. Patients with defective MMR (dMMR) status have improved survival and do not benefit from 5-fluorouracil (5-FU) therapies. In contrast, patients with a proficient MMR (pMMR) status have a higher risk of recurrence and worse survival. The pMMR patients are then further stratified on the basis of MACC1 gene expression. Patients with a pMMR status and a low MACC1 expression have a favorable prognosis similar to patients having a dMMR status, whereas patients having a pMMR status and high MACC1 expression have a less favorable prognosis.
-
-
-
-
-
-
-
搜索结果
8 条记录 (耗时 0.024 秒)
